Policies & RegulationsPharmacyHospitalsPharma & DistributionDrug ApprovalsIP IssuesDomestic NDD
  news bulletin  
Four drugmakers challenge Celebrex patent
by Eui Kyoung Yoon (ekyeun@dreamdrug.com)
Published : Nov 24, 2014 14:09:11
Yuhan, Daewoong, Hanmi and Chong Kun Dang challenges Pfizer’s patent for Celebrex, sources said on November 23.

The patent on the substance of Celebrex expires in June 2015, but the patent of the composition expires in 2019. The four companies now try to invalidate the patent of the composition to roll out their generic versions early.

Many pharmaceutical companies got marketing approval for their generic versions of Celebrex before the patent-approval linkage system gets effective next year, but they can’t market them because the patent on the composition is valid till 2019.

If those four companies win the case, they will be able to enter the market first. Celebrex sales are about 50 billion won annually.
Reply 0
Name Password
Popular News
Champix to be covered, starting Feb 2015
First generic version of Omacor approved
OTC drugs will be available at some resorts
Novartis Korea and KPWA agreed on margin increase
MSD’s new COX-2 inhibitor Arcoxia approved
All materials contained on this site are protected by Korean copyright law and may not be reproduced, distributed, transmitted,
displayed, published or broadcast without the prior consent of dailypharm.com